What is Lifesci Capital's Estimate for DBVT Q3 Earnings?

Key Points

• Analysts at Lifesci Capital have significantly decreased their Q3 2025 earnings per share (EPS) estimate for DBV Technologies to ($1.25), down from a prior forecast of ($0.70).
• DBV Technologies' current full-year earnings consensus estimate is expected to be ($7.05) per share, reflecting ongoing financial challenges for the company.
• Shares of DBV Technologies have seen a decline of 9.5%, with the stock currently trading at around $8.51, compared to a 12-month high of $12.78.

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Analysts at Lifesci Capital decreased their Q3 2025 EPS estimates for DBV Technologies in a research note issued on Wednesday, July 30th. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings of ($1.25) per share for the quarter, down from their previous estimate of ($0.70). Lifesci Capital has a "Strong-Buy" rating on the stock. The consensus estimate for DBV Technologies' current full-year earnings is ($7.05) per share. Lifesci Capital also issued estimates for DBV Technologies' Q4 2025 earnings at ($1.25) EPS, FY2025 earnings at ($5.40) EPS and FY2026 earnings at ($1.65) EPS.

Other analysts have also issued reports about the stock. JMP Securities restated a "market outperform" rating and set a $21.00 target price on shares of DBV Technologies in a research report on Thursday, June 26th. HC Wainwright lifted their price target on shares of DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a report on Monday, May 5th. The Goldman Sachs Group raised shares of DBV Technologies to a "sell" rating and set a $7.25 price target on the stock in a report on Thursday, May 29th. Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a report on Tuesday, May 27th. Finally, Wall Street Zen downgraded shares of DBV Technologies from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Two analysts have rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $14.75.

DBV Technologies Trading Down 9.5%

Shares of NASDAQ DBVT opened at $8.51 on Friday. The firm has a 50 day moving average of $9.48 and a 200 day moving average of $7.38. The firm has a market capitalization of $233.09 million, a price-to-earnings ratio of -1.78 and a beta of -0.59. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $12.78.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.34). The business had revenue of $1.74 million for the quarter, compared to the consensus estimate of $0.64 million. DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.